Sonoma Pharmaceuticals Inc (SNOA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sonoma Pharmaceuticals Inc (SNOA) has a cash flow conversion efficiency ratio of -0.380x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.30 Million) by net assets ($3.43 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sonoma Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Sonoma Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Sonoma Pharmaceuticals Inc total liabilities for a breakdown of total debt and financial obligations.
Sonoma Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sonoma Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Korab Resources Ltd
AU:KOR
|
-0.163x |
|
Signing Day Sports, Inc.
NYSE MKT:SGN
|
60.761x |
|
Constellation Technologies Ltd
AU:CT1
|
0.038x |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
1.063x |
|
Keystone Law Group PLC
LSE:KEYS
|
0.375x |
|
Greenwave Technology Solutions Inc. Common Stock
NASDAQ:GWAV
|
-0.100x |
|
BioRestorative Therapies Inc
NASDAQ:BRTX
|
-1.315x |
|
Qiiwi Games AB (publ)
ST:QIIWI
|
-0.078x |
Annual Cash Flow Conversion Efficiency for Sonoma Pharmaceuticals Inc (2005–2025)
The table below shows the annual cash flow conversion efficiency of Sonoma Pharmaceuticals Inc from 2005 to 2025. For the full company profile with market capitalisation and key ratios, see SNOA company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $4.41 Million | $-88.00K | -0.020x | +94.89% |
| 2024-03-31 | $6.14 Million | $-2.40 Million | -0.391x | +49.33% |
| 2023-03-31 | $7.98 Million | $-6.15 Million | -0.771x | -57.89% |
| 2022-03-31 | $8.70 Million | $-4.25 Million | -0.488x | +22.45% |
| 2021-03-31 | $5.36 Million | $-3.38 Million | -0.630x | +22.84% |
| 2020-03-31 | $5.62 Million | $-4.59 Million | -0.816x | +26.92% |
| 2019-03-31 | $10.49 Million | $-11.72 Million | -1.117x | -37.63% |
| 2018-03-31 | $15.33 Million | $-12.44 Million | -0.812x | -112.98% |
| 2017-03-31 | $21.43 Million | $-8.17 Million | -0.381x | +55.82% |
| 2016-03-31 | $10.14 Million | $-8.75 Million | -0.863x | -55.32% |
| 2015-03-31 | $12.05 Million | $-6.69 Million | -0.555x | -36.99% |
| 2014-03-31 | $12.06 Million | $-4.89 Million | -0.405x | -243.85% |
| 2013-03-31 | $4.08 Million | $1.15 Million | 0.282x | -93.93% |
| 2012-03-31 | $-868.00K | $-4.03 Million | 4.645x | +278.40% |
| 2011-03-31 | $1.70 Million | $-4.43 Million | -2.604x | -176.30% |
| 2010-03-31 | $7.04 Million | $-6.64 Million | -0.942x | +87.30% |
| 2009-03-31 | $2.27 Million | $-16.83 Million | -7.418x | -556.02% |
| 2008-03-31 | $15.43 Million | $-17.45 Million | -1.131x | +6.81% |
| 2007-03-31 | $14.90 Million | $-18.08 Million | -1.213x | +56.61% |
| 2006-03-31 | $7.34 Million | $-20.52 Million | -2.796x | +54.50% |
| 2005-03-31 | $2.20 Million | $-13.53 Million | -6.146x | -- |
About Sonoma Pharmaceuticals Inc
Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally. It offers Lumacyn, a skin toner; Regenacyn, a prescription scar gel; Reliefacyn to alleviate red bumps, rashes, shallow skin f… Read more